Literature DB >> 6816753

Non-A, non-B hepatitis not following transfusion: a study of hospital patients in Jerusalem.

M Shalit, R Tur-Kaspa, R Adler, N Manny, S Shraga, A Morag, M Eliakim.   

Abstract

An analysis of the etiology of acute viral hepatitis in 172 hospitalized patients showed that 70.9% suffered from hepatitis A (HA), 12.2% from hepatitis B (HB), 1.7% from infectious mononucleosis and 15.1% (26 cases) from non-A, non-B hepatitis. Patients who had received blood transfusions during the 6 mo preceding the onset of the disease were not included in the present survey. The male:female ratio in the patients with non-A, non-B hepatitis was 1:88; 73% were Ashkenazic and 27% non-Ashkenazic Jews. The ethnic distribution of patients with non-A, non-B hepatitis was similar to that of patients with HA but differed from that of HB patients (only 41% Ashkenazic). Thirty-eight percent of the non-A, non-B group had had contact with jaundiced patients during the 6 mo preceding the onset of the disease, and 46% were students or soldiers. The clinical course of the disease was, on the whole, milder than that of HB and similar to that of HA. Since many cases of non-A, non-B hepatitis are anicteric, it is concluded that the disease is a significant problem in Israel.

Entities:  

Mesh:

Year:  1982        PMID: 6816753

Source DB:  PubMed          Journal:  Isr J Med Sci        ISSN: 0021-2180


  3 in total

1.  Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity.

Authors:  G M Ginsberg; D Shouval
Journal:  J Epidemiol Community Health       Date:  1992-12       Impact factor: 3.710

2.  Non A, non B hepatitis in the aged.

Authors:  M Sonnenblick; R Oren; R Tur-Kaspa
Journal:  Postgrad Med J       Date:  1990-06       Impact factor: 2.401

3.  Cost-benefit analysis of a nationwide inoculation programme against viral hepatitis B in an area of intermediate endemicity.

Authors:  G M Ginsberg; S Berger; D Shouval
Journal:  Bull World Health Organ       Date:  1992       Impact factor: 9.408

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.